Active, not recruitingPhase 2NCT04221503
Niraparib/TTFields in GBM
Studying Astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Intervention
- Niraparib(drug)
- Enrollment
- 30 target
- Eligibility
- 22 years · All sexes
- Timeline
- 2019 – 2026
Study locations (1)
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Tesaro, Inc. · NovoCure Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04221503 on ClinicalTrials.govOther trials for Astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07552467Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGEARLY PHASE1NCT07284069Senicapoc and Perampanel for Newly Diagnosed GlioblastomaAarhus University Hospital
- RECRUITINGPHASE2NCT05653635Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II StudyCentre Paul Strauss
- RECRUITINGPHASE1NCT07343986Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated GlioblastomaUniversity of Virginia
- RECRUITINGPHASE2NCT07417761Tuvusertib in Astrocytoma With ATRX MutationGrupo Español de Investigación en Neurooncología
- RECRUITINGNANCT06466031Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]Copernicus Memorial Hospital
- RECRUITINGNANCT06930846HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)Dartmouth-Hitchcock Medical Center
- RECRUITINGPHASE3NCT07100730Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaTelix Pharmaceuticals (Innovations) Pty Limited